Aging, Metabolism, Synaptic Activity, and Aβ in Alzheimer's Disease
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nanomolar levels of soluble Aβ oligomers are known to be highly cytotoxic and mediate damage via a number of cellular pathways, including the formation of Aβ membrane channels [29,30].”
From Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Synaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“For example, the initial active vaccine clinical trial against Aβ pointed to engagement of the antibodies by plaque reduction via microglia degradation without however any corresponding cognitive improvement (Holmes et al., 2008).”
BackgroundObesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 1×
“Although vascular disease risk factors, such as obesity and diabetes, increase the risk for dementia (Kivipelto et al., 2005), there are less clear links between vascular risk factors and the more characteristic biomarker and pathological alterations that reflect AD.”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 1×
“Experimental therapeutic studies have also shown that central signaling pathways important for aging can be targeted for improvement in AD transgenic models, including modulation of mTOR (Caccamo et al., 2010; Ma et al., 2010; Spilman et al., 2010) and AMPK (Wang et al.”
BackgroundIntraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 2×
“A newer but controversial insight into early AD pathology, which can also help explain the different CSF biomarker and brain pathology trajectories, as well as the anatomical disconnect between Aβ and tau pathologies, was the finding of early accumulation of Aβ42 within AD vulnerable neurons (Gouras et al., 2000).”
BackgroundSelf-citationPalmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706
Self-citationOligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain
Takahashi, R. H., Almeida, C. G., Kearney, P. F., Yu, F., Lin, M. T., Milner, T. A., & Gouras, G. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5167-03.2004 · Cited by 445
Self-citation
Research works printed but not linked: 14
- Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med., 367795, 10.1056/NEJMoa1202753 · DOI · Paper page
- Buchhave, 2012, Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia, Arch. Gen. Psychiatry, 69, 98, 10.1001/archgenpsychiatry.2011.155 · DOI · Paper page
- Cataldo, 2000, Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations, Am. J. Pathol., 157, 277, 10.1016/S0002-9440(10)64538-5 · DOI · Paper page
- DeKosky, 1990, Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity, Ann. Neurol., 27, 457, 10.1002/ana.410270502 · DOI · Paper page
- Guimas Almeida, 2018, Impact of late-onset Alzheimer's genetic risk factors on β-amyloid endocytic production, Cell. Mol. Life Sci, 75, 2577, 10.1007/s00018-018-2825-9 · DOI
- Kobro-Flatmoen, 2016, Reelin-immunoreactive neurons in entorhinal cortex layer II selectively express intracellular amyloid in early Alzheimer's disease, Neurobiol. Dis., 93, 172, 10.1016/j.nbd.2016.05.012 · DOI · Paper page
- Li, 2004, Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice, J. Neurochem, 89, 1308, 10.1111/j.1471-4159.2004.02455.x · DOI · Paper page
- Melnikova, 2013, Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis, J. Neurosci., 33, 3765, 10.1523/JNEUROSCI.4251-12.2013 · DOI
- Mohajeri, 2002, Passive immunization against β-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation, J. Biol. Chem., 277, 33012, 10.1074/jbc.M203193200 · DOI · Paper page
- Small, 2017, Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer's disease, Trends Neurosci., 40, 592, 10.1016/j.tins.2017.08.003 · DOI · Paper page
- Tampellini, 2010, Effects of synaptic modulation on β-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice, J. Neurosci, 30, 14299, 10.1523/JNEUROSCI.3383-10.2010 · DOI · Paper page
- Thal, 2002, Phases of Aβ-deposition in the human brain and its relevance for the development of AD, Neurology, 58, 1791, 10.1212/WNL.58.12.1791 · DOI · Paper page
- Wang, 2019, Therapeutic potential of AMP-activated protein kinase in Alzheimer's disease, J. Alzheimers. Dis., 68, 33, 10.3233/JAD-181043 · DOI
- Welikovitch, 2018, Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex, Acta Neuropathol, 136, 901, 10.1007/s00401-018-1922-z · DOI
Cited by
Wang, J., Fourriere, L., & Gleeson, P. A. (2024) · Biochemical Journal · doi:10.1042/bcj20240056 · Cited by 27
Metadata
- Authors
- Gouras, G. K.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-07-23
- Volume
- 11
- ISSN
- 1663-4365
- Cited by
- 10
- References
- 18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aging, Metabolism, Synaptic Activity, and Aβ in Alzheimer's Disease. https://app.cochat.ai/papers/10.3389/fnagi.2019.00185
- The paper
- Gouras, G. K. (2019). Aging, Metabolism, Synaptic Activity, and Aβ in Alzheimer's Disease. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2019.00185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.